Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | BMC Cancer

Figure 3

From: Biomarkers for antitumor activity of bevacizumab in gastric cancer models

Figure 3

Differences in the bioactivity of human VEGF in bevacizumab-sensitive tumors and bevacizumab-insensitive tumor SC-10-JCK. The bioactivity of VEGF in tumors was determined by the VEGFR2 phosphorylation of HUVEC treated with tumor tissue homogenate administered with bevacizumab or human IgG using western blot (A) and ELISA (B). Each VEGF level in the homogenate was shown in Figure 3A and B.

Back to article page